May 7th 2024
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Response letter received regarding new drug application for kidney cancer agent
June 17th 2013AVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
Closer surveillance, treatment needed in bladder Ca
June 3rd 2013More intense surveillance and treatment in the first 2 years after a bladder cancer diagnosis could reduce the number of patients whose cancer recurs and lower the death rate from this disease, according to researchers from UCLA’s Jonsson Comprehensive Cancer Center.
Partial nephrectomy shows increased survival benefit
April 15th 2013A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.
Metastatic renal cell carcinoma agent nearly doubles survival
April 15th 2013A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Novel VEGF inhibitor may play role in advanced renal cell carcinoma
March 6th 2013Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.
Study: Surveillance is safe for small renal masses
February 19th 2013A large retrospective study of older patients diagnosed with small kidney tumors showed that patients who undergo surgery to remove these tumors have the same risk of dying of kidney cancer over a 5-year period as those who undergo surveillance.
Zero-ischemia nephrectomy appears safe, efficacious
February 2nd 2013A technique of zero-ischemia robotic partial nephrectomy (RPN) using near-infrared fluorescence imaging appears to be associated with better postoperative kidney function compared with conventional RPN with main-artery renal clamping.
Thermal ablation common for small renal masses
February 2nd 2013Findings from a recent survey cement the idea that urology departments at academic centers have adopted thermal ablation as an alternative for management of patients with small renal masses, say researchers from the University of Wisconsin, Madison.
Bladder cancer remission improved by adding electromotive mitomycin to BCG
December 31st 2012In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.
Minimally invasive RPLND safe, efficacious in testis cancer
December 31st 2012Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.